A number of other analysts have also recently weighed in on THOR. Analysts at Raymond James reiterated an “outperform” rating on shares of Thoratec in a research note on Thursday. They now have a $30.00 price target on the stock, down previously from $41.00. Separately, analysts at Leerink Swann reiterated an “outperform” rating on shares of Thoratec in a research note on Thursday. They now have a $35.00 price target on the stock, down previously from $40.00. Finally, analysts at Oppenheimer cut their price target on shares of Thoratec from $41.00 to $35.00 in a research note on Thursday. They now have an “outperform” rating on the stock. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $37.18.
FEATURED Mawson Finland Provides Update on Exploration Activities at Rajapalot • Aug 21, 2024 9:06 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM
Avant Technologies to Implement Robust Cybersecurity Measures for AI-Driven Healthcare Solutions • AVAI • Aug 21, 2024 8:00 AM
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM